Literature DB >> 319220

Mutagenic activities in vitro and in vivo of five antischistosomal compounds.

R P Batzinger, E Bueding.   

Abstract

Five antischistosomal compounds--hycanthone, two of its chloroindazole analogs (IA-4 and IA-4 N-oxide), oxamniquine, and metrifonate--were tested for mutagenic activity, using Salmonella typhimurium strains TA 98 and TA 100 under in vitro and in vivo (host-mediated) conditions. In all assay systems hycanthone exhibited by far the highest mutagenic potency. Although oxamniquine and metrifonate had low metagenic activity in vitro and although their administration resulted in urine of low metagenic activity, their host-mediated mutagenic activities on strain TA 100 were fairly high. Confirming earlier studies with a less sensitive Salmonella strain, TA 1535, IA-4 N-oxide was found to be less metagenic than IA-4. Orally administered IA-4 and IA-4-oxide were less mutagenic under in vivo conditions than an equal dose administered intramuscularly. By contrast, the antihistosomal activity of a given dose of each compound was the same, regardless of which of these two routes was used, suggesting that mutagenic and antischistosomal effects are produced by different metabolites. The observations reported in this paper provide additional evidence that mutagenic activities can be dissociated from desired chemotherapeutic effects by suitable structural modifications.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 319220

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  2 in total

1.  Covalent binding and glutathione depletion in the rat following niridazole (ambilhar) pretreatment.

Authors:  I N Oduah; M I Thabrew; G O Emerole
Journal:  Arch Toxicol       Date:  1985-04       Impact factor: 5.153

2.  Drug metabolism in hepatosplenic schistosomiasis in the Sudan: a study with antipyrine.

Authors:  M Homeida; S Y Salih; R A Branch
Journal:  Gut       Date:  1978-09       Impact factor: 23.059

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.